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ttp://dx.doi.org/10.1016/j.jmoldx.2013.02.006Fragile X is the most common inherited cause of intellectual disability and is frequently associated with
autism. The syndrome is due to mutations of the FMR1 gene that result in the absence of fragile X
mental retardation protein (FMRP). We have developed a rapid, highly sensitive method for quantifying
FMRP from dried blood spots and lymphocytes. This assay uses two new antibodies, a bacterially
expressed abbreviated FMRP standard, and a Luminex platform to quantify FMRP. The assay readily
distinguished between samples from males with fragile X full mutations and samples from normal males.
It also differentiated mosaic from nonmosaic full-mutation male samples. This assay, because of its
methodology and minimal cost, could be the basis for newborn or population screening. (J Mol Diagn
2013, 15: 508e517; http://dx.doi.org/10.1016/j.jmoldx.2013.02.006)Supported by funds from the New York State Ofﬁce of People with
Developmental Disabilities.
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Portions of this work were presented at the 13th International Fragile X
Conference in Miami, Florida (July 25e29, 2012).The fragile X syndrome (FXS) (OMIM 309550) results from
the absence of fragile X mental retardation protein (FMRP).
This lack of expression is most commonly due to the
expansion of a CGG repeat in the 50-untranslated region of
the fragile X mental retardation gene (FMR1) to more than
200 repeats (the full mutation), which leads to hyper-
methylation of the FMR1 gene promoter and silences tran-
scription.1e5 In very rare cases, the syndrome is due to partial
or complete deletion of the FMR1 gene or to point mutations
within it.2,6,7 FMR1 alleles are highly polymorphic and are
classiﬁed by CGG repeat size. Normal FMR1 alleles (6 to 44
repeats) rarely change in repeat number on transmission.
Intermediate FMR1 alleles (45 to 54 repeats) may show a low
level of instability,8,9 which is inﬂuenced by the AGG
interruption pattern,10 but the intermediate alleles very
rarely change repeat size class. Individuals with pre-
mutation alleles (55 to 200 repeats) have normal or
somewhat reduced FMRP levels, but have increased FMR1
mRNA11 that is translated with reduced efﬁciency.12,13
Premutation alleles are highly unstable and may expand
to the full mutation in one generation when transmitted by
a female. Premutation carrier prevalence in North Amer-
ican populations was estimated at approximately 1 in 151
females and 1 in 468 males in a population-based samplestigative Pathology
.of 6747 Wisconsin adults.14 The full-mutation allele, with
>200 repeats, has an estimated prevalence of 1 in 3600 to
4000 males and 1 in 4000 to 6000 females (http://www.
fragilex.org/fragile-x-associated-disorders/prevalence, last
accessed April 25, 2013). Some individuals are mosaic,
having both the full mutation and a premutation in blood
cells15 (mosaic full mutation). The rate of adaptive skills
development is two to four times greater in mosaic cases
than in full-mutation cases.16
At present, there is no newborn screening for fragile X in
the United States, although pilot projects are underway.16,17
Despite the availability of commercial molecular fragile X
diagnostic testing, the average age at which the fragile X
syndrome is diagnosed in males has remained unchanged, at
approximately 36 months.17,18 Delay in diagnosis prevents
FXS Immunoscreening of DBS by Luminexearly therapeutic intervention for affected individuals and
genetic counseling for their families. Early detection may
become even more critical if pharmacological therapies
speciﬁc for fragile X that are currently in phase 2 or 3
clinical trials19 prove effective. Here, we describe an inex-
pensive immunoassay based on a Luminex (Austin, TX)
platform that detects FMRP in dried blood spots (DBS), as
well as in fresh human lymphocytes and other tissue
samples. The assay accurately measures FMRP in a DBS
sample and can identify males with the full mutation with
sensitivity and speciﬁcity approaching 100%. This highly
accurate test could be the basis for a fragile X test for
newborn screening, as well as for population studies of
fragile X.
Materials and Methods
Subjects
Blood samples were obtained from individuals being eval-
uated for fragile X at the New York State Institute for Basic
Research in Developmental Disabilities (IBR) or were
samples received at the Specialty Clinical Laboratory at IBR
for fragile X DNA analysis. Control blood samples were
obtained from IBR staff volunteers who were conﬁrmed to
be of normal genotype by DNA analysis. This study was
approved by the Institutional Review Board of IBR.
DBS
Blood was spotted onto ID bloodstain cards BFC180
(WB100014; GE Healthcare, Piscataway, NJ), using
a syringe with an 18-gauge needle. Cards were dried over-
night and stored in low-gas-permeable plastic bags with
desiccant packs, according to DBS guidelines and published
protocols.20,21 Moisture, heat, and direct sunlight are detri-
mental to the stability of DBS.20,22
Elution of FMRP from DBS
Three 6.9-mm-diameter disks (37.4 mm2) were cut from
each card with a paper punch (MCG503, 1/4 inch; McGill,
Marengo, IL) and then were transferred into a microtube.
Proteins were eluted in 200 mL of extraction reagent (Pierce
M-PER mammalian protein extraction reagent; Thermo
Fisher Scientiﬁc, Rockford, IL) containing 150 mmol/L
NaCl, 10 mg/mL chymostatin, 10 mg/mL antipain, and 1
protease inhibitor cocktail (Complete mini tablets, EDTA-
free; Roche Applied Science, Indianapolis, IN) by shaking
for 3 hours at room temperature. After a brief centrifugation
at 10,000  g, the eluates were decanted by pipette, and 50
mL was used in the assay. This 50 mL corresponds to an
eluate from 28.0 mm2 (ie, 25% of three 6.9-mm disks). The
assay was reliably performed with eluates from samples as
small as a 3-mm disk (7.1 mm2). A 3-mm-diameter disk was
cut from each ID card with a Harris Micro-PunchThe Journal of Molecular Diagnostics - jmd.amjpathol.org(LabSource, Romeoville, IL). Each disk was placed into
a well of low-protein-binding Durapore MultiScreen 96-
well ﬁlter plates (EMD Millipore, Billerica, MA), and
protein was eluted with agitation at 4C overnight in 50 mL
of extraction reagent (as above). Eluates were collected by
centrifugation into a 96-well catch plate and were used in
the Luminex assay. We compared the Luminex results for
eluates from 30 randomly chosen 3-mm disks with the 28.0-
mm2 eluate. The FMRP levels detected in the 3-mm disk
eluate were consistently 25% of the FMRP detected in the
28-mm2 eluate (r Z 0.91).
Lymphocyte and Lymphoblastoid Extracts
Blood samples (6 to 8 mL) were collected in Vacutainer
CPT tubes with citrate anticoagulant (BD, Franklin Lakes,
NJ), and lymphocytes were isolated within 2 hours of blood
collection, according to the manufacturer’s instructions. Cell
pellets were stored at 70C. For protein preparation,
pellets were lysed in extraction reagent (as above). After
a brief sonication, cell debris was removed by centrifugation
at 16,000  g for 15 minutes; the protein concentration in
the supernatant was determined using a Pierce BCA protein
assay (Thermo Fisher Scientiﬁc). Long-term lymphoblas-
toid cells were collected at 400  g, washed in PBS, and
frozen at 70C. Extracts were prepared as described for
lymphocytes.
Antibodies
The mouse monoclonal antibody (mAb) 6B8 was generated
by immunizing mice with a human FMRP expressed in Sf9
insect cells infected by a recombinant baculovirus.23 The
baculovirus (generously provided by M. Toth) included the
entire human FMRP open reading frame, which was in-frame
with six copies of a His tag; this baculovirus was used to
prepare high-titer viral stocks. Sf9 cells (grown in suspen-
sion at 27C) were infected with the baculovirus and cells
were harvested at 72 hours after infection. Recombinant
FMRPwas puriﬁed from lysed cells by nickelenitrilotriacetic
acid column chromatography (Ni-NTA puriﬁcation system;
Life TechnologieseInvitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Three male FVB Fmr1tm1Cgr
mice were immunized four times at 3-week intervals by
subcutaneous injection of 100 mg of recombinant FMRP in
TiterMax adjuvant (CytRx, Norcross, GA). Mice received
additional injections of 50 mg antigen in PBS for three
consecutive days before animal sacriﬁce and spleen removal.
After splenocyte fusion to cells of the NSOmyeloma cell line
(ATCC, Manassas, VA), cells were processed as described
previously to clone hybridomas producing anti-FMRP
mAbs.24,25 Several anti-FMRP mAbs were isolated, charac-
terized (LaFauci et al, unpublished data), and puriﬁed from
ascites ﬂuid by protein G spin column chromatography
(Pierce kit 89979; Thermo Fisher Scientiﬁc) according to the
manufacturer’s instructions. Clone 6B8, used in the present509
LaFauci et alstudy, recognized full-length human FMRPwith high afﬁnity
and speciﬁcity.
Rabbit anti-FMRP polyclonal antibody R477 was ob-
tained by immunizing rabbits with the oligopeptide
DDHSRTDNRPRNPREAK, which corresponds to a region
of the carboxyl terminus of human FMRP spanning residues
554 to 570. This oligopeptide was conjugated to KLH and
injected subcutaneously to two 8-week-old, 5-pound (w2.27
kg) female New Zealand rabbits (Charles River Laboratories
International, Wilmington, MA) in Freund’s complete adju-
vant, followed by four immunizations at 2- to 3-week inter-
vals. Rabbits were tested for the presence of anti-FMRP
antibodies by enzyme-linked immunosorbent assay using
96-well plates coated with 5 mg/mL of oligopeptide conju-
gated to OVA. One rabbit’s serum had the highest titer
(R477). This antibody was puriﬁed from serum using a Pierce
Melon Gel IgG puriﬁcation system (Thermo Fisher Scien-
tiﬁc) according to the manufacturer’s instructions. Both mAb
6B8 and R477, are available on request. Chemicon anti-
FMRP mAb 1C3 (MAB2160) and mouse anti-GAPDH
(MAB374) were purchased from EMD Millipore. Goat
anti-rabbit phycoerythrin-conjugated IgG (P2771MP) was
purchased from Life TechnologieseInvitrogen.
Recombinant Fusion Protein for FMRP Quantiﬁcation
A glutathione S-transferase (GST) fusion protein carrying the
epitopes of mAb 6B8 and R477 was constructed in two steps.
First, a double-stranded oligomer encoding a nine-amino-
acid sequence of FMRP (amino acids 344 to 352) that
includes the mAb 6B8 epitope was cloned into vector pGEX-
4T (GE Healthcare) using the BamHI and EcoRI sites.
Second, the resulting plasmid was modiﬁed to include the
R477 epitope by ligating (at EcoRI and XhoI sites) an FMR1
sequence corresponding to amino acids 546 to 605. The latter
sequence was obtained by PCR using a cloned FMR1 cDNA
and primers 50-CGGAATTCCGTGGAGGAGGCTTCAA-
30 and 50-CCCTCGAGCAGCCGACTACCTTCCACTG-30
(forward and reverse, respectively). Plasmids in bacterial
clones that expressed proteins recognized by both antibodies
(pGEX-hFMR1-SR7) were isolated and expressed in E. coli
strain BL21 by isopropyl b-D-1-thiogalactopyranoside
(IPTG) induction. The fusion protein, GST-SR7, was
puriﬁed by glutathione-Superﬂow resin (Clontech Labora-
tories, Mountain View, CA) according to the manufac-
turer’s instructions. Eluted GST-SR7 was dialyzed against
25 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl buffer,
concentrated in an Amicon Ultra-15 10K centrifugal ﬁlter
device (EMD Millipore), aliquoted, lyophilized, and stored
at 70C.
Luminex Assay Procedure
The mAb 6B8 was coupled to 5  106 xMAP MicroPlex
microspheres (Luminex) according to the manufacturer’s
instructions. Assays were prepared in low-protein-binding510Durapore MultiScreen 96-well ﬁlter plates (EMD Milli-
pore). Each well contained a total volume of 100 mL,
including 50 mL DBS eluate or cell lysate (3 mg total protein
in 50 mL) and 3000 mAb 6B8ecoupled microspheres
resuspended in 50 mL assay buffer [PBS pH 7.4 containing
1% bovine serum albumin (Biosource; Life Tech-
nologieseInvitrogen) 0.05% Tween 20, and 0.05% sodium
azide]. Plates were incubated in the dark with shaking in
a Multi-MicroPlate Genie mixer (Scientiﬁc Industries,
Bohemia, NY) for 5 hours at room temperature. The
supernatant was removed using a vacuum manifold
(MultiScreen HTS vacuum manifold kit; EMD Millipore),
and the microspheres were washed and incubated with the
detecting antibody R477 (1.76 mg/mL in 100 mL assay
buffer) at 4C overnight. Supernatant was aspirated, and
the microspheres washed and incubated with 100 mL of
2 mg/mL goat anti-rabbit IgG conjugated to phycoerythrin
for 2 hours at room temperature with agitation. Finally,
microspheres were resuspended in 100 mL assay buffer and
were analyzed (in duplicate) using a Luminex 200 system.
FMRP Concentration
Dilutions of GST-SR7 were used to generate a standard
curve for each plate using MiraiBio MasterPlex QT quan-
titative analysis software for protein assay (version 2.5;
Hitachi Solutions America, South San Francisco, CA).
Median ﬂuorescence intensity was plotted against GST-SR7
concentrations. The amount of FMRP in the DBS was re-
ported as concentration (pmol/L) in the DBS extract. A
concentration of 1 pmol/L FMRP in the assay well is
equivalent to 5.7 pmol/L in the original blood sample.
Western Blot Analysis
Protein samples (15 mg) were analyzed on precast 4% to 15%
polyacrylamide Criterion Tris-HCl gels (BioRad Laborato-
ries, Hercules, CA) that were run at 200 mV for 1 hour.
Separated proteins were transferred onto 0.22-mm poly-
vinylidene diﬂuoride membranes (BioRad Laboratories) in
transfer buffer (25 mmol/L Tris, 192 mmol/L glycine, pH
8.3) using a semidry electroblotter (OWL HEP-1; Thermo
Scientiﬁc, Waltham, MA) for 1 hour at 10 V. Membranes
were incubated in 5% nonfat dry milk in 0.01 mol/L Tris pH
7.5, 0.137 mol/L NaCl, 0.05% Tween 20 and then with either
anti-FMRP antibodies or a mouse anti-GAPDH mAb. After
washing, membranes were incubated for 1 hour with the
conspeciﬁc alkaline phosphataseeconjugated secondary
antibodies (Sigma-Aldrich, St. Louis, MO). Proteins were
detected with CDP-Star reagent (New England Biolabs,
Ipswich, MA) according to the manufacturer’s instructions.
DNA Studies
Fragile X analysis of DNA isolated from blood samples was
performed by PCR and Southern blot as describedjmd.amjpathol.org - The Journal of Molecular Diagnostics
FXS Immunoscreening of DBS by Luminexpreviously26e28 or with AmplideX FMR1 PCR (RUO)
reagents (Asuragen, Austin, TX) and capillary electropho-
resis29 according to the manufacturer’s instructions. DBS
DNA was isolated with a DNeasy kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions and was
concentrated by precipitation with ethanol.
Statistical Analysis
DBSs from blood received more than 3 days after collection
were excluded from the analysis because of protein degra-
dation. A cord-blood sample DBS was excluded because of
a very high FMRP level and because of the unique nature of
this sample. Premutation male data are given in Table 1, but
were not included in the analysis because there was only
one of these samples. Data were analyzed with either SPSS
11 Statistics (SPSS, Chicago, IL) or SigmaPlot version 11
(Systat Software, San Jose, CA) software.
Results
Antibody Characterization
To develop a DBS immunoassay, we needed one antibody
to capture FMRP and another to detect it within a complex
background of other proteins. Preliminary experiments
suggested mAb 6B8 and R477 as a candidate pair. The
speciﬁcity of these antibodies was characterized by Western
blot analysis of extracts from normal (male and female),
premutation (female), and full-mutation (male) lymphocytes
(Figure 1A). Three FMRP bands (68 to 80 kDa) were
recognized by the mAb 6B8 with short exposure in normal
and premutation samples, whereas no bands were detected
in the full-mutation FXS male extract (Figure 1A). This
indicated that 6B8 has little if any cross-reactivity with the
closely related proteins FXR1P and FXR2P,30 as seen with
long exposure (overexposure) (Figure 1A). Bands of theTable 1 Capture Immunoassay Quantiﬁcation of FMRP in DBS Extracts
Mutation Fragile X Genotype
Genotype* No.
Protein concentration
Mean Median
Male (n Z 103)
Normal 85 25.8 24.8
Premutation 1 ND ND
Full mutation 17 1.7 0.7
Nonmosaic 10 0.6 0.6
Mosaic 7 3.3 2.9
Female (n Z 112)
Normal 49 26.0 25.3
Premutation 59 23.0 22.5
Normal þ premutation 108 24.3 23.6
Full mutation 4 17.2 16.7
M normal þ F normal 134 25.9 25.0
*Genotype determined by PCR and Southern analyses.
F, female; M, male; CI, conﬁdence interval; Max, maximum; Min, minimum; ND
The Journal of Molecular Diagnostics - jmd.amjpathol.orgsame size (68 to 80 kDa) were detected by R477 in all
extracts except the male full-mutation FXS (Figure 1B).
This antibody also detected a few faint bands, especially one
at approximately 65 kDa, that were visible on overexposure
(Figure 1B), indicating that R477 has weak cross-reactivity
to a few other proteins. Comparison with the pattern
detected by the commercially available anti-FMRP mAb
1C3 (Figure 1C) suggests that the mAb 6B8 and R477 are
both highly speciﬁc for FMRP. Thus, mAb 6B8 and R477
both recognize FMRP without having any other targets in
common.Luminex Immunoassay
We evaluated the capacity of this antibody pair to capture
and detect FMRP in Luminex immunoassays of extracts
from normal human lymphoblastoid cell lines. Microspheres
were coupled to the mAb 6B8 to capture FMRP, and R477
was used to detect its presence. To evaluate the assay, we
used 1.2 to 80 mg of protein extracted from normal and full-
mutation male lymphoblastoid cell lines. The level of FMRP
in normal cells was proportional to the amount of sample
(Figure 1D), and there was a linear (r2Z 0.98) response up
to approximately 40 mg of extract. Only background ﬂuo-
rescence values were detected in wells containing up to
80 mg of male full-mutation extracts.
To gauge the effectiveness of the Luminex assay, we
analyzed the level of FMRP among blood samples from
different normal individuals. Repeated assays of 19
lymphocyte extracts were highly correlated (r Z 0.96),
indicating that the assay is reliable (data not shown). In
addition, the relative levels of FMRP detected by densito-
metric quantiﬁcation of the short-exposure mAb 6B8e
stained bands (Figure 1A) very closely matched (within
7%) the relative levels in those samples measured by the
Luminex assay.Derived from 215 Individuals with Normal, Premutation, and Full-
(pmol/L)
SD Min Max 95% CI
10.3 8.6 51.5 23.6e28.0
ND 29.0 29.0 ND
1.7 0.2 6.6 0.8e2.6
0.3 0.2 1.2 0.40.7
1.6 1.8 6.6 1.8e4.8
8.6 11.6 46.3 23.5e28.4
7.0 9.9 38.7 21.2e24.8
7.9 9.9 20.1 22.8e25.8
2.0 15.4 20.1 14.0e20.5
9.6 8.6 51.5 24.2e27.5
, not determined.
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Figure 1 Detection with two antibodies highly speciﬁc for FMRP. AeC:
Detection of FMRP with short and long exposure. Lane 1, normal male; Lane
2 normal female; Lanes 3 and 4, premutation females; lane 5, full-mutation
male. GAPDH is the protein loading control. The arrowheads on the right
show positions of MW markers. A: With mAb 6B8, three FMRP bands
(marked by bullets between lanes 2 and 3) were detected in all but the full-
mutation male extract. B: Similar bands were detected with R477. The
asterisk indicates the position of the 65 kDa background band. C: Detec-
tion of FMRP with commercially available mAb 1C3. D: Luminex assay
detection of FMRP in normal and fragile X lymphoblastoid cell extracts.
Linear response of the mAb 6b8eR477 assay to increasing amounts of
normal cell extract up to 40 mm (triangles); fragile X full-mutation cell
extract (squares) showed background ﬂuorescence values up to 80 mm. E:
Schematic of the abbreviated FMRP standard, GST-SR7. This protein was
engineered to include the epitopes recognized by the mAb 6B8 and R477.
F: The response of the Luminex assay to increasing amounts of GST-SR7
shows linearity from 0 to 280 pmol/L. Mean ﬂuorescence intensity MFI
Z 24.497 pmol/L þ 295.33. R2 Z 0.99.
LaFauci et alThe assay demonstrated a broad FMRP distribution in 11
lymphocyte samples from normal individuals; mean ﬂuo-
rescence intensity ranged from 1194 to 2375 (SD, 405.1). A
lymphocyte extract from a full-mutation male showed only
background ﬂuorescence value (data not shown) and was
easily distinguished from normal samples. We found that
lymphocyte samples are very sensitive to the length of time
between blood draw and lymphocyte isolation, as well as to
blood storage conditions, as has also been observed by
others.31 Only lymphocyte samples that were isolated within
a few hours of blood draw gave dependable results. The
requirements for rapid lymphocyte isolation from freshly
drawn blood made lymphocyte samples impractical for
FMRP screening.
Because of these limitations and in view of reports that
proteins are stable for at least 6 months in DBS that are
stored with desiccant,20 we tried using DBS eluates; we
were surprised to ﬁnd that FMRP was easily detectable in
these samples. In an initial experiment, DBS from four
normal individuals and three premutation females averaged
approximately 100-fold higher than three male full-mutation
samples and approximately 10-fold higher than a male
mosaic full-mutation sample (data not shown). The level of
FMRP detected in DBS also depended on storage condi-
tions. Proteins are stable for at least 6 months when DBS are512stored as recommended (with desiccant at 22C or 4C).20,22
Even in the absence of desiccant, DBSs (nZ 8) retained on
average 66% of the original FMRP after 1 year of storage at
room temperature.
Quantiﬁcation of FMRP
For FMRP quantiﬁcation and to control for technical vari-
ations in capture and detection, we constructed an abbre-
viated FMRP reference protein for inclusion in the assay as
a standard. We used a series of GST-fusion proteins that
carried discrete regions of FMRP to localize the mAb 6B8
and R477 epitopes (LaFauci et al, unpublished data) and
constructed a GST fusion protein, GST-SR7, that included
both epitopes (Figure 1E). Puriﬁed GST-SR7 at concentra-
tions of 0.5 to 280 pmol/L resulted in a linear response
(R2 Z 0.99) in the Luminex assay (Figure 1F). Repeat
analyses of GST-SR7 aliquots during 4 months of storage
at 70C were highly correlated (r Z 0.996), which indi-
cated that this standard was stable and did not aggregate
during this period.
We used a standard curve calculated from dilutions of
a known amount of GST-SR7 to measure the amount of
FMRP present in DBS samples from 215 individuals with
normal, premutation, or full-mutation genotypes (Table 1).
FMRP levels are reported as concentration (pmol/L) in the
50-mL extracts used in the assays, which are equivalent to
8.7 mL of whole blood. As with lymphocytes, assays of
duplicate extracts of 57 randomly selected DBS were
highly correlated (r Z 0.96), indicating that the assay is
reliable. In individuals with normal FMR1 alleles, the
FMRP level appears to be normally distributed (Figure 2A),
with no difference between males and females. The level
of FMRP detected in the assay declines with age from
infants to preteens; it then appears to level off in teenage
years and remains relatively unchanged through adulthood
(Figure 2B).
In males with a full-mutation allele, the mean FMRP level
was 1.7 pmol/L (6% of normal), with a maximum of 6.6
pmol/L (26% of normal) (Table 1). There was no overlap
between full-mutation and normal levels (Figure 3A), and
the difference between the two groups was highly signiﬁ-
cant (P < 0.001, U-test). Receiver operating characteristic
(ROC) analysis showed that, at a cutoff of 7.59 pmol/L,
sensitivity and speciﬁcity were both 100% (CIZ 79.41% to
100.0% and 94.72% to 100.0%, respectively). The sensi-
tivity and speciﬁcity are biased, because they are based
on the data set used to construct the ROC curve rather than
on an independent test set and are therefore optimistic.
Nonetheless, the analysis does indicate that a cutoff can be
chosen that will make false negatives extremely unlikely,
without generating an unwieldy number of false positives.
The full-mutation male samples included full-mutation
mosaic samples, which have a signiﬁcantly higher level
of FMRP (Figure 3B) (P Z 0.001, U-test). The separation
between the mosaic and nonmosaic full-mutation samplesjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 FMRP in DBS from normal individuals. A: Distribution of FMRP
concentration in 134 normal male and female DBS extracts. Mean FMRP
concentration (by comparison with the GST-SR7 standard) is 25.9  9.7
pmol/L. B: FMRP concentration in DBS by age of donor.
Figure 3 FMRP in DBS from males. A: FMRP concentration in normal
males and fragile X full-mutation (FXS) males. B: FMRP concentration in
nonmosaic and mosaic FXS males. C: Southern analysis of mosaic FXS
showing premutation alleles. Lane 1, normal allele EagIeEcoRI fragment of
2.8 kb which contains CGG triplet repeat and probe (StB12.3) sequence
(right side of schematic at bottom). Lane 2, full-mutation alleles EcoRI
fragments of approximately 8.5 kb which contain >200 CGG triplet repeats
and are not cleaved by EagI, because of methylation (asterisk). Lane 3,
mosaic full-mutation including full-mutation alleles as in lane 2 and also
premutation alleles EagIeEcoRI fragments of approximately 3 kb which
contain <200 CGG triplet repeats and are cleaved at the EagI site (which is
unmethylated in these alleles). Box-plot data (A and B) are expressed as
25th to 75th percentile, median, and maximum and minimum, with outliers
shown as circles. ***P  0.001, U-test.
FXS Immunoscreening of DBS by Luminex(Figure 3B) indicates that the Luminex assay readily
distinguishes between them. The level of FMRP detected
in the Luminex assay is consistent with the intensity of the
premutation band in the Southern blot analysis of the
mosaic full-mutation male (Figure 3C). The sample pop-
ulation included only one premutation male, which is too
few to allow comparison of this group with the normal
population.
The FMRP level was shifted down in females with a full-
mutation allele (Figure 4), and their mean (17.2 pmol/L)
was signiﬁcantly different from the mean (26.0 pmol/L) in
normal allele females (P Z 0.032, U-test) (Table 1). In
females with a premutation allele, the mean FMRP level
appeared to be lower than normal, but the difference did not
reach signiﬁcance (P Z 0.09, U-test) (Figure 4).
Discussion
The immunoassay described in this report readily identiﬁed
all 17 male fragile X full-mutation samples among DBSs
from 215 individuals with normal, premutation, and full-
mutation alleles. The capture and detection antibodies in theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgassay (ie, mAb 6B8 and R477) are highly speciﬁc for
FMRP. The absence of other shared target proteins is key to
the speciﬁcity and sensitivity of the assay. The FMRP levels
in the 215 cases matched their fragile X genotypes as
determined by Southern blot and PCR. The FMRP levels in513
Figure 4 FMRP in DBS from females. FMRP concentration differed sig-
niﬁcantly between normal and full-mutation females (*PZ 0.032, U-test).
Although the median FMRP value for premutation females was lower than
normal, this comparison did not reach signiﬁcance (PZ 0.09, U-test).
LaFauci et althe control population DBS (n Z 134) exhibited an
approximately Gaussian distribution, similar to that reported
for platelets.31,32 Sex had no effect on the FMRP level
detected (Table 1) (P Z 0.5, U-test). In adults, age had no
detectable effect on FMRP level (Figure 2B). In infants and
preteens, however, there was a higher level of the protein,
which was inversely correlated to age and decreased to adult
levels in the teen years (Figure 2B). Because a DBS sample
corresponds to a speciﬁc volume of blood (w0.3 mL/mm2;
ID blood stain card BFC180), the progressive FMRP
decrease from infants to teens is probably due the reduction
seen in the leukocyte count in children as they age.33,34 In
addition to accounting for the decrease in FMRP with age in
normal children, this explanation also suggests that one factor
inﬂuencing the variability of FMRP in normal adults is the
leukocyte count, which varies with a variety of factors,
including body mass index, hyperlipidemia, smoking, infec-
tion, inﬂammation, stress, hypertension, impaired glucose
tolerance, and allergy.35,36 Reduced FMRP has also been re-
ported in brain samples of subjects with autism, schizophrenia,
major depression, and bipolar disorder,37,38 although it is not
known if this decrease is paralleled in blood.
The level of FMRP in male full-mutation individuals
(n Z 17) ranged between 0.2 and 6.6 pmol/L; it did not
overlap with and was signiﬁcantly lower than the level in
controls (Figure 3A), indicating that the assay can identify
full-mutation males with sensitivity and speciﬁcity that
would be more than adequate for newborn or population
screening. Moreover, full-mutation mosaic and nonmosaic
males were also well separated, thus allowing the differen-
tiation of individuals with mosaic alleles from those with
nonmosaic full-mutation alleles (Figure 3B).
The assay detects a level of FMRP in mosaic FXS males
that corresponds to the degree of mosaicism seen in
Southern analysis (Figure 3C). This suggests that, although
there is no overlap in the male DBS sample illustrated in
Figure 3A, the true population range of FMRP levels in
FXS males may overlap with normal in exceptional cases
that have unusual Southern blot patterns.39e41 We estimate514from DNA diagnostic data (644 full-mutation males) that
less than 1% of FXS males may show expression in the
normal range (S. Nolin and A. Glicksman, personal
communication). Although FXS mosaicism (ie, the pres-
ence of FMR1 premutation alleles in some somatic cells) is
relatively common,42 the presence of mosaicism does not
necessarily predict a higher level of adaptive functioning.43
This is presumably due to the marginal amount of FMRP
expressed in most mosaics or, in some cases, to differences
in the extent of mosaicism in different tissues.44,45
The mean FMRP level detected in full-mutation females
differs signiﬁcantly from that of normal females but, in
contrast to males (Figure 4), the range overlaps with
normal. Variation in X inactivation is assumed to be the
explanation for the broad range of impairment in full-
mutation females.46,47 In human females, X inactivation
results in a ratio of paternal and maternal X chromosome
expression that is highly variable, exceeding 70:30 in 25%,
80:20 in 8%, and 90:10 in 2% of DNA samples from
normal females.48 Our assay shows a shift in the distri-
bution of FMRP levels in full-mutation females that is
consistent with this variability (Figure 4). The present
analysis, however, is based on a limited number of full-
mutation females and the true range of FMRP probably
extends below the normal level. There is evidence that, in
full-mutation females, the inactivation ratio in blood
correlates with the level of impairment49 and that, in full-
mutation males and females, the level of FMRP corre-
lates with full-scale intelligence quotient.50 This suggests
that direct measurement of FMRP in DBS may be
a predictor of cognitive status.
Premutation females appeared to have a slightly lower
than normal level of FMRP, but the difference did not reach
signiﬁcance. Other studies have shown a reduced level of
FMRP in premutation carriers, both male and female.12,13
Although they have reduced FMRP, both males and
females who carry FMR1 premutation alleles have increased
levels of FMR1 mRNA and an increased risk, especially in
males, for fragile Xeassociated tremor/ataxia syndrome
(FXTAS) and fragile Xeassociated primary ovarian insuf-
ﬁciency (FXPOI) in females.51
Application of the immunoassay to DBS samples greatly
expands its potential usefulness. DBSs have been used
since the 1960s to preserve both proteins and DNA for
detection of metabolic and genetic disorders.52,53 DBS
samples require only a few drops of blood on a ﬁlter card,
which can then be stored and transported at ambient
temperature.
The Luminex assay described here is a rapid and direct
quantitative measurement of FMRP that identiﬁes males
with full mutations with virtually 100% speciﬁcity and
sensitivity. The assay is economical, amenable to high-
throughput analysis, and is very likely to be an effective
method for screening of newborn infants and other pop-
ulations. We assayed eluates from 28 mm2 of DBS for the
results reported here, but we determined that the 3-mm (7.1jmd.amjpathol.org - The Journal of Molecular Diagnostics
FXS Immunoscreening of DBS by Luminexmm2) DBS samples commonly used in screenings yield
25% of this amount. Thus, analysis of 3-mm DBS samples
will still allow identiﬁcation of full-mutation males, partic-
ularly for samples from newborns, whose protein levels tend
to be elevated. Screening for FXS in children with cognitive
impairments, developmental delays, and autism is already
recommended by the American Academy of Pediatrics,54
but, primarily because effective speciﬁc treatment is lack-
ing, it is not currently recommended for newborn
screening.16,18,55 This situation is likely to change in the
near future, because a number of drugs are currently in
phase 2 and 3 trials to test their efﬁcacy and safety as tar-
geted treatments for FXS; these include AFQ056 (Novartis),
R04917523 (HofmanneLa Roche), arbaclofen (Seaside
Therapeutic), donepezil hydrochloride (Stanford Uni-
versityeNIMH), and minocycline (University of Cal-
iforniaeDavis). It is likely that one or more of the drugs
currently being developed or tested will lead to an effective
pharmacological treatment for FXS and thus could lead to
the addition of FXS to newborn screening panels. This will
depend in part on the availability of a test that is appropriate
for newborn screening, such as one using the method we
have described here.
Assays of FMRP in fresh blood samples have been
described previously,31,32 but these techniques depend on
isolation of lymphocytes or platelets from plasma, which
may limit their applicability to large-scale fragile X
screening. Methods that analyze the number of FMR1
CGG repeats or the methylation status of FMR1 alleles
have been used in DBS screening of high-risk populations
or in pilot newborn screening. In the CGG repeat-number
assays, DNA extracted from a DBS is ampliﬁed by PCR
and the products are analyzed by capillary electrophoresis,
agarose gel electrophoresis, or mass spectrometry.56e59
For FMR1 methylation analysis, DNA from DBS disks is
treated with sodium bisulﬁte, and screened by real-time
methylation-speciﬁc PCR.60 These DNA-based methods
can accurately identify expanded triplet-repeat alleles by
direct sizing or by their methylation status, and may
identify premutation carriers and full-mutation females in
addition to full-mutation males. These assays may,
however, be too complicated or expensive to be used in
routine newborn screening.
The Luminex assay described here is economical and
could readily be converted to a high-throughput application.
It assays the level of FMRP directly, and may thus be
a better prognostic indicator than DNA-based assays. It
readily identiﬁes full-mutation males and may identify full-
mutation females who are likely to be impaired, but further
studies will be needed to determine whether a low level of
FMRP detected in a female is indicative of impairment due
to a full mutation. Samples that are positive in this Luminex
screen can then be subjected to molecular analysis of DBS
DNA. Thus, this assay has the potential to be an extremely
effective method for screening populations for full-mutation
FXS males.The Journal of Molecular Diagnostics - jmd.amjpathol.orgAcknowledgment
We thank Michael Flory for assistance with statistical anal-
ysis and for helpful suggestions.
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